Skip to main
  1. Stocks
  2. Adlai Nortye Ltd
  3. Forecast
ANL

ANL Stock Forecast & Price Target

ANL Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Adlai Nortye is attractive fundamentally because it has two clinically differentiated, high-upside RAS assets: AN9025, a pan-RAS(ON) inhibitor with strong preclinical potency and a Phase 1 readout expected in 1H27, and AN4035, the first pan-RAS(ON) ADC dosed in humans with FDA “Study-May-Proceed” support and first patient dosing in Australia. The company’s strategy targets a large RAS-driven market spanning colorectal, pancreatic, and lung cancers, where systemic RAS inhibition has been constrained by on-target toxicity, and AN4035’s CEACAM5-directed delivery may widen the therapeutic window and improve combinability. Valuation remains asymmetric versus larger peers, with a market cap around $0.7B versus $35B and $3.8B for comparable RAS developers, while the stock had already risen 700% YTD against 10% for XBI.

Bears say

Adlai Nortye is viewed negatively because its lead RAS program, AN9025, still lacks clinical validation despite strong preclinical data, leaving open the possibility that its higher affinity and long half-life could create toxicity that undermines the therapeutic window. The company’s intermittent-dosing thesis remains clinically unproven, and the fact that pan-RAS inhibition also affects healthy tissue raises persistent risks of rash, mucositis, GI toxicity, dose interruptions, and dose reductions that could weaken both efficacy and combination potential. In addition, the panRAS(ON) space is IP-sensitive, so freedom-to-operate uncertainty may limit strategic interest, while the broader pipeline remains early and unproven relative to competitors.

ANL has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Adlai Nortye Ltd and is not a guaranteed prediction by Public.com or investment advice.

ANL Analyst Forecast & Price Prediction

Get the latest ANL stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ANL

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Adlai Nortye Ltd (ANL) Forecast

Analysts have given ANL a Strong Buy based on their latest research and market trends.

According to 5 analysts, ANL has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Adlai Nortye Ltd (ANL)


ANL Analyst Forecast & Price Prediction

Get the latest ANL stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ANL

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ANL stock data and trends